Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$574,000Cash on Hand
CF+ Cash Runway
Follow CAPS by emailGet an email when CAPS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CAPS, unsubscribe in one click. Privacy
📣 What CAPS Says Is Next
in 2026 · “Management expects these drivers to be reflected in financial results beginning early in 2026, with a positive corporate EBITDA run-rate targeted starting in Q2 2026.”
Company press release, Jan 28, 2026 · SEC filing
in 2026 · “What specific operational levers are expected to drive margin expansion in 2026, and when should investors expect to see those improvements reflected in financial results?”
Company press release, Jan 28, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Q3 2026 revenue rose 46% to $20.0M and income from operations was $0.4M, including about $0.4M of one-time tariff refunds. FY2026 revenue guidance was cut to about $70M from $72.1M, citing higher interest rates that slowed housing. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Financing Capstone extended the maturity of its October 2025 convertible note with 3i from October 22, 2026 to December 13, 2027, with about $900,000 principal outstanding. It also extended its Tumim common stock purchase agreement to January 1, 2028. Form 8-K · SEC filing · Press release
Oct 30, 2026 ·
Financing Capstone Holding proposes to register 333,333 common shares for resale by a selling stockholder under an equity line financing. The company receives no proceeds from the resale. Shares trade on Nasdaq as CAPS after a 1-for-30 reverse split effective October 19, 2026. Form S-1 · SEC filing
Oct 21, 2026 ·
Listing Capstone Holding Corp. effected a 1-for-30 reverse stock split, effective October 19, 2026, reducing outstanding common stock from about 27,536,950 to about 917,898 shares. Trading continues on Nasdaq under CAPS with new CUSIP 14068E307. Form 8-K · SEC filing · Press release
Oct 13, 2026 ·
Restructuring Capstone Holding Corp. completed its redomicile from Delaware to Nevada effective October 9, 2026, with shares converted one-for-one and stock certificates still valid. Shareholder rights now fall under Nevada law and new charter documents, which differ from Delaware law. Form 8-K · SEC filing
Oct 1, 2026 ·
Earnings Capstone reported preliminary July and August 2026 results: organic revenue rose 7.6% to $14.0 million and organic gross profit rose 6.5% to $3.5 million. Year-to-date through August, organic revenue rose 4.6% to $48.1 million and organic gross profit rose 6.5% to $12.5 million. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2010 · Phase 2 · Results Expected · A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients Registry primary completion date, not a results date
Sep 2010 · Phase 2 · Results Expected · A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars Registry primary completion date, not a results date
Jul 2010 · Phase 2 · Results Expected · A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CAPS holds $574,000 in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Share count 935,385 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CAPS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CAPS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.